Trial Condition(s):

Atrial Fibrillation

Observational study to assess sociodemographic and clinical features of patients treated with rivaroxaban in routine clinical practice of hematologists, cardiologists and internists of Spain (HEROIC)

Bayer Identifier:

17671

ClinicalTrials.gov Identifier:

NCT02262676

EudraCT Number:

Not Available

Study Completed

Trial Purpose

Depict demographic and clinical features of patients with atrial fibrillation treated with rivaroxaban to prevent stroke and pulmonary embolism in routine clinical practice

Inclusion Criteria
- Patients ≥ 18 years
 - Patients with atrial fibrillation 
 - Patients in treatment with rivaroxaban for stroke prevention in atrial fibrillation at least 3 months previous to inclusion period in study
Exclusion Criteria
- Patients in treatment after start of study
 - Patients treated with other anticoagulant treatment

Trial Summary

Enrollment Goal
2251
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Xarelto (Rivaroxaban, BAY59-7939)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Spain

Status
Completed
 

Trial Design